How to avoid the costly M&A pitfalls of IP recordals

Global mergers and acquisitions activity is surging, especially in the pharmaceutical and semiconductor sectors. In these industries, intellectual property – not physical factories – drives most company value. Pharmaceutical firms eyeing patent cliffs are buying late-stage clinical assets to replace expiring assets. Meanwhile, semiconductor leaders are pursuing deals to secure AI architectures. Ultimately, a deal’s success depends on one thing: the ability to legally prove ownership of the acquired patents...

Read the News